Gyre Therapeutics (Gyre Therapeutics) COGS-to-Revenue : 0.04 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics COGS-to-Revenue?

Gyre Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was $4.6 Mil. Its Revenue for the six months ended in Dec. 2023 was $113.5 Mil.

Gyre Therapeutics's COGS to Revenue for the six months ended in Dec. 2023 was 0.04.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Gyre Therapeutics's Gross Margin % for the six months ended in Dec. 2023 was 95.91%.

Gyre Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Gyre Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics COGS-to-Revenue Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

COGS-to-Revenue

0.04

0.05

0.04

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
COGS-to-Revenue	0.04	0.05	0.04

Gyre Therapeutics COGS-to-Revenue Calculation

Gyre Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.636	/	113.45
	=	0.04

Gyre Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.636	/	113.45
	=	0.04

Gyre Therapeutics (NAS:GYRE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Gyre Therapeutics's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	4.636 / 113.45
	=	95.91 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Gyre Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023